Get the Stockscreener App
2.41
3.88%
0.09
Prokidney Corp stock is traded at $2.41, with a volume of 1.57M.
It is up +3.88% in the last 24 hours and down -20.98% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.32
Open:
$2.35
24h Volume:
1.57M
Relative Volume:
0.13
Market Cap:
$325.33M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-4.2281
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+2.12%
1M Performance:
-20.98%
6M Performance:
+60.67%
1Y Performance:
+10.55%
1-Day Range:
$2.35
$2.475
1-Week Range:
$2.215
$2.59
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.41 | 342.88M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Trend Dashboard Flags ProKidney Corp. As Potential Swing TradeJuly 2025 Final Week & Weekly Watchlist for Hot Stocks - beatles.ru
Published on: 2025-08-21 03:49:33 - newsyoung.net
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
Is ProKidney Corp. subject to activist investor interestAnalyst Upgrade & Smart Swing Trading Alerts - newsyoung.net
What are ProKidney Corp.’s recent SEC filings showingJuly 2025 WrapUp & Daily Risk Controlled Trade Plans - thegnnews.com
Chartists Watching For Breakout in ProKidney Corp.Trade Volume Report & Fast Gain Swing Alerts - newsyoung.net
Live Scanner Shows Breakout on ProKidney Corp.Index Update & Weekly High Return Stock Opportunities - metal.it
ProKidney reports Q2 EPS (13c), consensus (14c) - MSN
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
Is This a Bottoming Phase for ProKidney Corp.July 2025 Pullbacks & Fast Entry Momentum Trade Alerts - sundaytimes.kr
Is ProKidney Corp. forming a bullish divergenceQuarterly Growth Report & Real-Time Chart Breakout Alerts - newsyoung.net
ProKidney reports larger second-quarter loss as key studies continue - Winston-Salem Journal
Citi Reaffirms Their Buy Rating on ProKidney (PROK) - The Globe and Mail
ProKidney Reports 78 Percent Gain in Q2 - sharewise.com
What are the key products or services offered by pro-kidney? - AInvest
ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook - TipRanks
ProKidney Corp. Reports Q2 2025 Financial Results - TipRanks
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewswire
ProKidney Q2: Rilparencel eGFR slope improves by 78%, topline PROACT 1 data in Q2 2027. - AInvest
ProKidney's Breakthrough: FDA Backs Fast-Track Path as Kidney Treatment Shows Strong Phase 2 Results - Stock Titan
ProKidney (PROK.O) Sees Sharp Intraday Drop — But No Fundamental Catalyst — What’s Really Behind the Move? - AInvest
ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy - MSN
ProKidney And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
ProKidney PROK 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth and Analyst Upgrades - AInvest
What institutional investors are buying ProKidney Corp. stockGet timely alerts on top-performing stocks - Jammu Links News
What is the dividend policy of ProKidney Corp. stockFree Technical Analysis Support - Jammu Links News
Is ProKidney Corp. stock overvalued or undervaluedInvest confidently with market-leading analysis - Jammu Links News
What catalysts could drive ProKidney Corp. stock higher in 2025Free Stock Market Return Analysis - Jammu Links News
What makes ProKidney Corp. stock price move sharplyGet daily updates on top-performing stocks - Jammu Links News
What are the technical indicators suggesting about ProKidney Corp.Get exclusive access to premium stock research - Jammu Links News
What analysts say about ProKidney Corp. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are analysts’ price targets for ProKidney Corp. in the next 12 monthsConsistent high-yield stocks - Jammu Links News
Is ProKidney Corp. a growth stock or a value stockHigh-margin investment plays - Jammu Links News
Is it the right time to buy ProKidney Corp. stockAchieve consistent profits with expert strategies - Jammu Links News
How volatile is ProKidney Corp. stock compared to the marketRapid growth opportunities - Jammu Links News
What are ProKidney Corp. company’s key revenue driversCapitalize on emerging market trends - Jammu Links News
When is ProKidney Corp. stock expected to show significant growthDiscover breakthrough trading strategies - Jammu Links News
How does ProKidney Corp. generate profit in a changing economyUnlock rapid growth potential in your portfolio - Jammu Links News
How does ProKidney Corp. compare to its industry peersHigh-octane investment opportunities await - Jammu Links News
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - 富途牛牛
What is ProKidney Corp. company’s growth strategyAdvanced Screener Planner For 2025 - Jammu Links News
Can ProKidney Corp. Regain Lost Ground This QuarterStep-by-Step Stock Investment Guide Gains Popularity - metal.it
How strong is ProKidney Corp. company’s balance sheetAdvanced Screener Planner For 2025 - jammulinksnews.com
How ProKidney Corp. stock performs during market volatilityWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
Published on: 2025-07-30 17:58:00 - beatles.ru
Published on: 2025-07-29 09:29:22 - metal.it
Wyckoff Accumulation Phase Possible in ProKidney Corp.Buy Low Sell High Stock Watch Strategy in Focus - metal.it
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):